Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer



      To report outcomes and identify predictors of toxicity in patients undergoing reirradiation with interstitial brachytherapy (ISBT) for recurrent cancers of the female reproductive tract.

      Methods and Materials

      Twenty-one patients received ISBT performed using 192Ir sources (10 low dose rate and 11 high dose rate) at our institution between 2009 and 2013. Demographic, disease specific, treatment, toxicity, and outcome data were collected. Kaplan–Meier and proportional hazard models were used to estimate survival and logistic regression to model toxicity. A least absolute shrinkage and selection operator penalty was used to identify relevant predictors of outcome and toxicity.


      Eleven patients had uterine cancer, 7 patients had cervical cancer, and 3 patients had vulvar cancer. One-year actuarial freedom from local–regional failure, progression-free survival (PFS), and overall survival were 71.5%, 66.0%, and 82.2%, respectively. Tumor size was a significant predictor of worse PFS and overall survival (1 cm increase in tumor size = hazard ratio [HR], 1.61; 95% confidence interval [CI]: 1.16, 2.62 for PFS; HR, 2.02; 95% CI: 1.21, 3.38). Grade 3 or higher vaginal, urinary, and rectal toxicity occurred in 28.5%, 9.5%, and 19% of patients, respectively. Urethra D0.1cc predicted for grade 2 or higher urinary toxicity (one equivalent dose in 2 Gy fraction increase = HR, 1.156; 95% CI: 1.001, 1.335).


      Reirradiation with ISBT is both safe and effective. In patients with recurrent cancer, urethra D0.1cc predicts for increased urinary toxicity. Increased tumor size is a negative prognostic factor in patients receiving ISBT for cancer recurrence.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cai G.
        • Zhu J.
        • Hu W.
        • Zhang Z.
        Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: Results of a phase II study.
        Radiat Oncol. 2014; 9: 278
        • Das P.
        • Delclos M.E.
        • Skibber J.M.
        • et al.
        Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
        Int J Radiat Oncol Biol Phys. 2010; 77: 60-65
        • Koom W.S.
        • Choi Y.
        • Shim S.J.
        • et al.
        Reirradiation to the pelvis for recurrent rectal cancer.
        J Surg Oncol. 2012; 105: 637-642
        • Lingareddy V.
        • Ahmad N.R.
        • Mohiuddin M.
        Palliative reirradiation for recurrent rectal cancer.
        Int J Radiat Oncol Biol Phys. 1997; 38: 785-790
        • Mohiuddin M.
        • Marks G.
        • Marks J.
        Long-term results of reirradiation for patients with recurrent rectal carcinoma.
        Cancer. 2002; 95: 1144-1150
        • Ng M.K.
        • Leong T.
        • Heriot A.G.
        • et al.
        Once-daily reirradiation for rectal cancer in patients who have received previous pelvic radiotherapy.
        J Med Imaging Radiat Oncol. 2013; 57: 512-518
        • Russell A.H.
        • Koh W.J.
        • Markette K.
        • et al.
        Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract.
        Gynecol Oncol. 1987; 27: 226-232
        • Dagoglu N.
        • Mahadevan A.
        • Nedea E.
        • et al.
        Stereotactic body radiotherapy (sbrt) reirradiation for pelvic recurrence from colorectal cancer.
        J Surg Oncol. 2015; 2: 23858
        • Dewas S.
        • Bibault J.E.
        • Mirabel X.
        • et al.
        Robotic image-guided reirradiation of lateral pelvic recurrences: Preliminary results.
        Radiat Oncol. 2011; 6: 77
        • Okazawa K.
        • Yuasa-Nakagawa K.
        • Yoshimura R.
        • et al.
        Permanent interstitial re-irradiation with au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma.
        J Radiat Res. 2013; 54: 299-306
        • Beriwal S.
        • Bhatnagar A.
        • Heron D.E.
        • et al.
        High-dose-rate interstitial brachytherapy for gynecologic malignancies.
        Brachytherapy. 2006; 5: 218-222
        • Beriwal S.
        • Rwigema J.C.
        • Higgins E.
        • et al.
        Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer.
        Brachytherapy. 2012; 11: 176-180
        • De Ieso P.B.
        • Mullassery V.
        • Shrimali R.
        • et al.
        Image-guided vulvovaginal interstitial brachytherapy in the treatment of primary and recurrent gynecological malignancies.
        Brachytherapy. 2012; 11: 306-310
        • Eisbruch A.
        • Johnston C.M.
        • Martel M.K.
        • et al.
        Customized gynecologic interstitial implants: CT-based planning, dose evaluation, and optimization aided by laparotomy.
        Int J Radiat Oncol Biol Phys. 1998; 40: 1087-1093
        • Erickson B.
        • Albano K.
        • Gillin M.
        CT-guided interstitial implantation of gynecologic malignancies.
        Int J Radiat Oncol Biol Phys. 1996; 36: 699-709
        • Thibault I.
        • Lavallee M.C.
        • Aubin S.
        • et al.
        Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: Clinical outcomes and dose–volume histogram analysis.
        Brachytherapy. 2012; 11: 181-191
        • Charra C.
        • Roy P.
        • Coquard R.
        • et al.
        Outcome of treatment of upper third vaginal recurrences of cervical and endometrial carcinomas with interstitial brachytherapy.
        Int J Radiat Oncol Biol Phys. 1998; 40: 421-426
        • Lee L.J.
        • Damato A.L.
        • Viswanathan A.N.
        Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance.
        Brachytherapy. 2013; 12: 303-310
        • Nag S.
        • Martinez-Monge R.
        • Copeland L.J.
        • et al.
        Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina.
        Gynecol Oncol. 1997; 66: 16-19
        • Tewari K.
        • Cappuccini F.
        • Brewster W.R.
        • et al.
        Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma.
        Gynecol Oncol. 1999; 74: 416-422
        • Weitmann H.D.
        • Knocke T.H.
        • Waldhausl C.
        • et al.
        Ultrasound-guided interstitial brachytherapy in the treatment of advanced vaginal recurrences from cervical and endometrial carcinoma.
        Strahlenther Onkol. 2006; 182: 86-95
        • Murakami N.
        • Kasamatsu T.
        • Sumi M.
        • et al.
        Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
        Radiat Oncol (London, England). 2014; 9: 31
        • Nag S.
        • Selman A.
        • Martinez-Monge R.
        • et al.
        Interstitial re-irradiation as salvage treatment for previously irradiated patients with recurrent gynecologic malignancies.
        Journal of Brachytherapy International. 1998; 14: 49-58
        • Kishi K.
        • Sonomura T.
        • Shirai S.
        • et al.
        Critical organ preservation in reirradiation brachytherapy by injectable spacer.
        Int J Radiat Oncol Biol Phys. 2009; 75: 587-594
        • Mabuchi S.
        • Takahashi R.
        • Isohashi F.
        • et al.
        Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: A single institutional experience.
        Int J Gynecol Cancer. 2014; 24: 141-148
        • Martinez-Monge R.
        • Cambeiro M.
        • Rodriguez-Ruiz M.E.
        • et al.
        Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer.
        Brachytherapy. 2014; 13: 219-224
        • Amsbaugh A.
        • Amsbaugh M.
        • Derhake B.
        • et al.
        Optimal epidural analgesia during interstitial brachytherapy for treatment of gynecologic cancer.
        Oncology. 2015; 29 ([abstract]): S58-S59
        • Potter R.
        • Haie-Meder C.
        • Van Limbergen E.
        • et al.
        Recommendations from gynaecological (gyn) gec estro working group (ii): Concepts and terms in 3d image-based treatment planning in cervix cancer brachytherapy-3d dose volume parameters and aspects of 3d image-based anatomy, radiation physics, radiobiology.
        Radiother Oncol. 2006; 78: 67-77
        • Fowler J.F.
        Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling.
        Int J Radiat Oncol Biol Phys. 2009; 73: 1532-1537
        • Friedman J.
        • Hastie T.
        • Tibshirani R.
        Regularization paths for generalized linear models via coordinate descent.
        J Stat Softw. 2010; 33: 1-22
        • Lee L.J.
        • Viswanathan A.N.
        Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
        Int J Radiat Oncol Biol Phys. 2012; 84: 1192-1197
        • Rajagopalan M.S.
        • Kannan N.
        • Kim H.
        • et al.
        Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer.
        Brachytherapy. 2013; 12: 248-253